Studied in a clinical trial evaluating 732 patients.

The ORATORIO trial for PPMS

The efficacy and safety of OCREVUS for primary progressive multiple sclerosis (PPMS) were studied in over 700 patients in a placebo-controlled trial.

OCREVUS® (ocrelizumab) for PPMS

Demonstrated effectiveness in PPMS

OCREVUS was proven in PPMS across key clinical and MRI measures of efficacy. 

Safety profile in the ORATORIO trial.

OCREVUS safety profile for PPMS

The safety of OCREVUS was studied and demonstrated in ORATORIO. Learn about the potential for adverse reactions, including infections, IRRs, and other serious adverse events.